Immunocore Holdings plc Other Comprehensive Income (Loss), Net of Tax
Immunocore Holdings plc (IMCR) reported Other Comprehensive Income (Loss), Net of Tax of $1.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- Immunocore Holdings plc other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was $1.04M, a 83.89% decline year-over-year.
- Immunocore Holdings plc other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$7.29M, a 1183.06% decline year-over-year.
- Immunocore Holdings plc other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$3.39M, a 204.47% decline year-over-year.
- Immunocore Holdings plc other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was $6.48M, a 586.02% increase year-over-year.
- Immunocore Holdings plc other comprehensive income (loss), net of tax for fiscal 2025 was $5.68M, a 127.34% increase from fiscal 2024.
- Immunocore Holdings plc other comprehensive income (loss), net of tax for fiscal 2024 was $2.50M, a 86.43% decline from fiscal 2023.
- Immunocore Holdings plc other comprehensive income (loss), net of tax for fiscal 2023 was $18.41M.
- Immunocore Holdings plc other comprehensive income (loss), net of tax for fiscal 2022 was -$24.36M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.04M 10-Q · filed 2026-08-06 | -$6.25M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$7.29M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $5.68M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | -$3.39M 10-Q · filed 2025-11-06 | $3.08M derived: sum of 2 quarters · filed 2026-08-06 | $3.76M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $6.48M 10-Q · filed 2026-08-06 | $7.15M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $673.00K 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $2.50M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $3.25M 10-Q · filed 2025-11-06 | $4.19M derived: sum of 2 quarters · filed 2025-11-06 | $5.09M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $944.00K 10-Q · filed 2025-11-06 | $1.84M 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | $897.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $18.41M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | -$14.95M 10-Q · filed 2024-11-06 | -$8.18M derived: sum of 2 quarters · filed 2024-11-06 | -$746.00K derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $6.77M 10-Q · filed 2024-11-06 | $14.21M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $7.43M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | -$24.36M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | -$254.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |